Human Cytomegalovirus-Specific T-Cell Immune Reconstitution in Preemptively Treated Heart Transplant Recipients Identifies Subjects at Critical Risk for Infection
暂无分享,去创建一个
G. Gerosa | G. Palù | L. Barzon | C. Mengoli | D. Abate | A. Gambino | G. Feltrin | G. Toscano | C. d'Agostino | M. Fiscon | A. Saldan | D. Sgarabotto | R. Cusinato | Simona Cofano
[1] G. Palù,et al. Diagnostic Utility of Human Cytomegalovirus-Specific T-Cell Response Monitoring in Predicting Viremia in Pediatric Allogeneic Stem-Cell Transplant Patients , 2012, Transplantation.
[2] C. Kotton. Management of cytomegalovirus infection in solid organ transplantation , 2010, Nature Reviews Nephrology.
[3] H. Einsele,et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. , 2010, Blood.
[4] L. Bonfante,et al. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. , 2010, The Journal of infectious diseases.
[5] Paul Aurora,et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[6] R. Fisher,et al. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation , 2009, Transplant infectious disease : an official journal of the Transplantation Society.
[7] R. Razonable,et al. Deficiency of cytomegalovirus (CMV)‐specific CD8+ T cells in patients presenting with late‐onset CMV disease several years after transplantation , 2009, Transplant infectious disease : an official journal of the Transplantation Society.
[8] A. Hansen,et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. , 2008, Blood.
[9] D. Snydman,et al. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. , 2008, Herpes : the journal of the IHMF.
[10] R. Hetzer,et al. Dissection of the CMV specific T‐cell response is required for optimized cardiac transplant monitoring , 2008, Journal of medical virology.
[11] S. Hunt,et al. The changing face of heart transplantation. , 2008, Journal of the American College of Cardiology.
[12] Richard D. Smith,et al. Human Cytomegalovirus Secretome Contains Factors That Induce Angiogenesis and Wound Healing , 2008, Journal of Virology.
[13] Holden T Maecker,et al. Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides , 2008, BMC Immunology.
[14] F. Baldanti,et al. Monitoring human cytomegalovirus infection in transplant recipients. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[15] C. Legendre,et al. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] J. Fishman. Infection in solid-organ transplant recipients. , 2007, The New England journal of medicine.
[17] H. Valantine,et al. Cardiac allograft vasculopathy and insulin resistance--hope for new therapeutic targets. , 2007, Endocrinology and metabolism clinics of North America.
[18] A. Yeung,et al. Changes in Coronary Arterial Dimensions Early After Cardiac Transplantation , 2007, Transplantation.
[19] J. Ernerudh,et al. Active cytomegalovirus replication in patients with coronary disease , 2007, Scandinavian cardiovascular journal : SCJ.
[20] H. Valantine,et al. T-Cell Immunity to Subclinical Cytomegalovirus Infection Reduces Cardiac Allograft Disease , 2006, Circulation.
[21] D. Lilleri,et al. Monitoring of Human Cytomegalovirus‐Specific CD4+ and CD8+ T‐Cell Immunity in Patients Receiving Solid Organ Transplantation , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[22] B. Narasimhan,et al. Acute Rejection and Cardiac Allograft Vascular Disease Is Reduced by Suppression of Subclinical Cytomegalovirus Infection , 2006, Transplantation.
[23] D. Lilleri,et al. Monitoring transplant patients for human cytomegalovirus: Diagnostic update. , 2006, Herpes : the journal of the IHMF.
[24] H. Schäfers,et al. Differences in CMV‐Specific T‐Cell Levels and Long‐Term Susceptibility to CMV Infection after Kidney, Heart and Lung Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[25] R. Razonable. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[26] R. Hetzer,et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1–specific CD8 T cells , 2005, The Journal of experimental medicine.
[27] G. Palù,et al. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real‐time quantitative DNA PCR assay: Correlation with pp67 RNA detection , 2004, Journal of medical virology.
[28] H. Valantine. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[29] H. Valantine. The Role of Viruses in Cardiac Allograft Vasculopathy , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[30] R. Hetzer,et al. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy , 2003, Transplantation.
[31] P. Häyry,et al. Cytomegalovirus and transplant arteriopathy: evidence for a link is mounting, but the jury is still out. , 2003, Transplantation.
[32] A. Branzi,et al. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study , 2003, Transplantation.
[33] R. Rubin. Overview: pathogenesis of fungal infections in the organ transplant recipient. , 2002, Transplant infectious disease : an official journal of the Transplantation Society.
[34] Holden T Maecker,et al. Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. , 2002, The Journal of infectious diseases.
[35] L. Picker,et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. , 2002, The Journal of infectious diseases.
[36] D. Weill. Role of cytomegalovirus in cardiac allograft vasculopathy , 2001, Transplant infectious disease : an official journal of the Transplantation Society.
[37] R. Speich,et al. Introduction to the Immunocompromised Host Society consensus conference on epidemiology, prevention, diagnosis, and management of infections in solid-organ transplant patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[38] M. Otero,et al. Cidofovir treatment of human polyomavirus‐associated acute haemorrhagic cystitis , 2001, Transplant infectious disease : an official journal of the Transplantation Society.
[39] D. Snydman,et al. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] X. Jin,et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL , 1996, Journal of virology.
[41] T. Finkel,et al. The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus , 1996, The Lancet.
[42] S. Riddell,et al. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus‐specific cytotoxic T lymphocytes , 1994, Journal of medical virology.
[43] R. Rubin. Preemptive therapy in immunocompromised hosts. , 1991, The New England journal of medicine.
[44] J. Niland,et al. A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow Transplants , 1991 .
[45] Silviu Itescu,et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[46] C. Payá. Indirect effects of CMV in the solid organ transplant patient. , 1999, Transplant infectious disease : an official journal of the Transplantation Society.
[47] J. Niland,et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group. , 1991, The New England journal of medicine.